Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Randomized Controlled Trial for Evaluating CYP2C19 Allele Genotype-guided Clopidogrel Treatment Outcomes in Real-world Practice After the ePCI

NCT06665919 is registered in ClinicalTrials.gov with Vistamedi Ltd. as lead sponsor.

NCT NCT06665919
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06665919 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Randomized Controlled Trial for Evaluating CYP2C19 Allele Genotype-guided Clopidogrel Treatment Outcomes in Real-world Practice After the ePCI
Lead sponsor
Vistamedi Ltd.
Phase
Not applicable
Overall status
Completed
Start date
June 15, 2023
Completion date
July 5, 2025
Enrollment
283 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

adverse cardiac events, bleeding, clopidogrel resistance, coronary artery disease, coronary thrombosis, death, death from cardiovascular disease, hospitalisations